For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Inpatients with persistent depressive disorder were recruited at a German University Hospital for a 10-week inpatient treatment with the Cognitive Behavioral Analysis System of Psychotherapy.
For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.
In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.